TOP TEN perturbations for 38626_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38626_at
Selected probe(set): 212601_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38626_at (212601_at) across 6674 perturbations tested by GENEVESTIGATOR:
colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)
Relative Expression (log2-ratio):-3.149067Number of Samples:24 / 3
| Experimental | colorectal cancer study 4 (recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up. |
colorectal cancer study 4 (non-recurring) / adjacent colon tissue (non-recurring)
Relative Expression (log2-ratio):-3.0390263Number of Samples:76 / 18
| Experimental | colorectal cancer study 4 (non-recurring) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients did not develop metastatic recurrence during follow-up after surgery. | |
| Control | adjacent colon tissue (non-recurring) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). No metastatic recurrence during follow-up. |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):2.7513657Number of Samples:2 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated p53HCT116 cell sample |
| Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
colorectal cancer study 25 / adjacent colon tissue
Relative Expression (log2-ratio):-2.7259455Number of Samples:94 / 17
| Experimental | colorectal cancer study 25 |
| Human primary colorectal carcinoma sample. | |
| Control | adjacent colon tissue |
| Normal colon tissue samples adjacent to tumor from patients with colorectal cancer. |
glioma study 17 (astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.608636Number of Samples:3 / 3
| Experimental | glioma study 17 (astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from low grade astrocytoma (grade II). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 36 ± 7 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):2.6070461Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.5716505Number of Samples:2 / 2
| Experimental | phenobarbital study 3 (10000uM) |
| Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code: | |
| Control | vehicle (medium) treated hepatocyte sample |
| Hepatocytes treated with vehicle (medium) for 24 hours. |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):2.5293846Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
colorectal cancer study 9 (metastatic progression) / adjacent colon tissue (metastatic progression)
Relative Expression (log2-ratio):-2.5101986Number of Samples:3 / 3
| Experimental | colorectal cancer study 9 (metastatic progression) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression. | |
| Control | adjacent colon tissue (metastatic progression) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). |
colorectal cancer study 4 (metastatic progression) / adjacent colon tissue (metastatic progression)
Relative Expression (log2-ratio):-2.451129Number of Samples:23 / 4
| Experimental | colorectal cancer study 4 (metastatic progression) |
| LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer with metastatic progression. | |
| Control | adjacent colon tissue (metastatic progression) |
| Histologically normal colon tissue samples from patients with primary colorectal cancer and metastatic progression collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). |